Moving from Ozempic to Wegovy: what actually changes, and why it matters

Why are Ozempic and Wegovy treated as different medicines if they contain the same ingredient?

It is a fair question, and one that confuses a lot of people. Ozempic and Wegovy both deliver semaglutide via a once-weekly subcutaneous injection, and the mechanism is identical: a GLP-1 receptor agonist that slows gastric emptying, raises feelings of fullness, and helps regulate blood sugar. What differs is the licensed indication and the dose ceiling. Ozempic is approved in the UK for type 2 diabetes management, with doses reaching 0.5mg or 1mg for most patients, and 2mg in some regimens. Wegovy carries a separate UK licence for weight management, with a maintenance dose of 2.4mg, more than double the most common Ozempic ceiling. As the NHS semaglutide medicines page explains, the two products are not interchangeable prescriptions, and switching between them requires a clinical decision by a prescriber. That matters because a GP managing your diabetes and a prescriber supporting your weight management are asking slightly different clinical questions, even though the drug in the pen is the same molecule.

This is also why Ozempic is not an appropriate route to weight-loss treatment. You can read more on the distinction between the two products on our Is Wegovy the same as Ozempic? page.

What actually changes when you move to the Wegovy dose schedule?

The titration ladder is the most practical difference. Wegovy starts at 0.25mg weekly for four weeks, then steps up through 0.5mg, 1.0mg and 1.7mg before reaching the 2.4mg maintenance dose, each step taking roughly four weeks. Someone transferring from Ozempic will already have some tolerance to semaglutide, but prescribers generally do not skip the lower Wegovy rungs; your gut still needs time to adjust at each new level, and rushing the titration is one of the more reliable ways to end up with significant nausea. The STEP 1 trial (published in the New England Journal of Medicine) put 2.4mg semaglutide against placebo over 68 weeks and found roughly 15% average body-weight reduction in adults with obesity but without type 2 diabetes. That figure comes from the full titrated schedule, not from a lower diabetes dose.

In April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, adding a further rung for eligible patients whose prescriber thinks they would benefit. Details on the specifics of each format are confirmed at consultation rather than assumed in advance, because clinical suitability shapes which dose makes sense for each person.

People who have been taking Ozempic off-label for weight loss (sometimes prompted by media coverage or supply shortages of Wegovy) often find the formal Wegovy pathway gives them clearer clinical oversight. Our guide on whether you can move from Ozempic to Wegovy covers the eligibility question in more detail.

Does moving to Wegovy mean starting the side effects all over again?

Not entirely, but it is realistic to expect some adjustment at each dose increase. The most common side effects of semaglutide at any dose are gastrointestinal: nausea, loose stools, constipation, reflux, and occasional vomiting. These tend to be most noticeable in the first week or two after a step-up and settle for most people once the body adapts. Moving from an Ozempic dose to the Wegovy schedule means you are stepping into territory your system has not experienced before, so the 1.7mg and 2.4mg increases in particular can bring a temporary return of nausea even if 1mg felt fine. Staying well hydrated and eating smaller portions helps; your prescriber and the Patient Information Leaflet are the right guides for anything persistent or severe.

If you are curious about how Saxenda-to-Wegovy switching compares with an Ozempic-to-Wegovy switch, the Saxenda to Wegovy guide covers the liraglutide-to-semaglutide transition in full. The side-effect profiles overlap significantly but the timing differs because liraglutide clears the body faster. One question our prescribers hear regularly: whether you can take a partial dose to manage tolerability. For context on that, the half-injection question page explains what the guidance says.

If Ozempic is not licensed for weight loss, what should you be using instead?

In the UK, two injectable medicines are licensed specifically for weight management in adults: Wegovy (semaglutide up to 2.4mg or 7.2mg) and Mounjaro (tirzepatide, a dual GIP and GLP-1 receptor agonist available up to 15mg). Both carry NICE recommendations and specific eligibility criteria. Neither is Ozempic. If you have been using Ozempic in a weight-loss context, the appropriate clinical step is a proper assessment under the Wegovy or Mounjaro pathway, with a prescriber who can review your history, confirm eligibility, and titrate correctly from the start.

You can read a fuller overview of the semaglutide treatment pathway or explore how the two licensed options compare on our weight-loss treatments overview. It is worth thinking about timing practically, too: if you are planning to start or transfer before a holiday or a long weekend, ordering before 12pm on a weekday means your consultation is reviewed the same day and the pen is with you the next working day, so you are not left in a gap.

Cost is a real consideration when switching, and private Wegovy pricing varies between providers. Our UK Wegovy cost guide explains what the market looks like and what a legitimate price should include. When you are ready to talk through your specific situation with a clinician, our prescribers are available through a free consultation, no obligation, and the review happens the same day.